Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity

This is a multi-center, open-label, single-arm, non-randomized study using a multi-timepoint triple tracer molecular imaging to characterize intra-patient cancer phenotypes between metastases and to monitor phenotypic plasticity non-invasively. This will be done using 18F-FDG, 68Ga-PSMA (or any other PSMA tracer) and 68Ga-DOTATATE in participants progressing with CRPC and showing at least 3 metastases after conventional imaging. Any PSMA tracer could be used but the first PSMA-PET scan determines the PSMA radiotracer that will be used throughout the study, in order to make the analysis of the radiographic evolution of metastases more accurate (e.g. 68Ga-PSMA-617 or 18F-DCF-PyL or 68Ga-PSMA-11). The reference imaging must have been performed either: 1) after biochemical progression on treatment OR 2) at least 90 days after last treatment has begun if imaging was performed while patient was still responding (to avoid disappearance of metastasis due to treatment response). These imaging will include: 1) bone scan or 18F-Na-PET/CT AND either chest/abdomen CT or chest CT and abdomen MRI OR 2) 18F-FDG-PET/CT. This study is planned to be conducted in up to 4 sites in Canada. Eligible participants (see Section for Eligibility Criteria) will be enrolled in a non-randomized, sequential manner, with competitive enrollment between study sites. A total of 45 participants will be accrued. Enrolled participants will undergo 18F-FDG, 68Ga- or 18F-PSMA and 68Ga-DOTATATE-PET/CT scans. After initial triple tracer PET molecular imaging, the participants will be treated with cabazitaxel or docetaxel or ARPI (as standard of care or as an investigational agent) or PSMA-radioligand therapy (as standard of care or as an investigational agent). Three (3) months after initiation of systemic therapy double-tracer (PSMA \& FDG) PET/CT imaging will be performed. Participants will continue their therapy and once progression will occur (V3, Progression 1), triple tracer will be repeated and a biopsy of a progressive lesion will be executed. Patients will be treated with a mandatory second line of approved mCRPC systemic therapies: PSMA-RLT therapy (Pluvicto 177Lu-PSMA-617) or Olaparib (PARPi) if they are found with homologous recombination repair (HRR) mutation (a predictive biomarker for PARPi). If not HRR mutated nor eligible to PSMA-RLT, a second line of approved mCRPC systemic therapy or research protocol will be offered. At Progression 2 (V4) (after treatment change following Progression 1), double-tracer 68Ga-PSMA and 18F-FDG PET/CT imaging will be repeated (DOTATATE scan will be optional). The patient will have another biopsy of a progressing lesion and an optional second biopsy of a non-progressing site offered.